Avalyn Pharma Inc | Targeted therapies for rare lung diseases
Avalyn is a clinical-stage biopharmaceutical company developing inhaled formulations of approved medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. By delivering drugs directly to the lungs via inhalation, Avalyn aims to improve efficacy and reduce systemic side effects compared to existing oral treatments. The company is led by CEO Lyn Baranowski and CSO Mark Surber, PhD.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2025
Sep 2023
Apr 2020
Jan 2017
Aug 2015
Create a free account to see which investors have funded this company.
Create Free Account
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
